Invesco Ltd. Sells 48,381 Shares of Option Care Health, Inc. $OPCH

Key Points

• Invesco Ltd. reduced its stake in Option Care Health, Inc. by 14.4%, owning approximately $10.02 million worth of shares as of the latest SEC filing.
• Option Care Health reported better-than-expected quarterly earnings with an EPS of $0.41, surpassing analysts' estimates of $0.40.
• Investment analysts have a consensus rating of "Moderate Buy" for Option Care Health, with an average target price set at $35.75.

Invesco Ltd. decreased its holdings in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 14.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 286,685 shares of the company's stock after selling 48,381 shares during the quarter. Invesco Ltd. owned approximately 0.18% of Option Care Health worth $10,020,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in Option Care Health by 17.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock valued at $92,518,000 after purchasing an additional 591,042 shares during the last quarter. Northern Trust Corp raised its position in shares of Option Care Health by 11.8% during the fourth quarter. Northern Trust Corp now owns 2,626,478 shares of the company's stock worth $60,934,000 after acquiring an additional 278,158 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Option Care Health by 4.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 2,609,705 shares of the company's stock worth $91,209,000 after acquiring an additional 99,574 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Option Care Health by 6,525,926.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 1,500,986 shares of the company's stock worth $52,459,000 after acquiring an additional 1,500,963 shares during the last quarter. Finally, Comerica Bank increased its holdings in Option Care Health by 13.1% in the fourth quarter. Comerica Bank now owns 1,357,628 shares of the company's stock valued at $31,497,000 after purchasing an additional 157,198 shares during the last quarter. Institutional investors own 98.05% of the company's stock.

Option Care Health Trading Down 0.9%

NASDAQ:OPCH traded down $0.26 on Friday, reaching $28.49. The company's stock had a trading volume of 656,226 shares, compared to its average volume of 1,853,735. Option Care Health, Inc. has a 1-year low of $21.39 and a 1-year high of $35.53. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.00 and a current ratio of 1.52. The firm has a market cap of $4.62 billion, a PE ratio of 22.79, a PEG ratio of 1.74 and a beta of 0.79. The business's 50-day moving average price is $29.66 and its two-hundred day moving average price is $31.67.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.40 by $0.01. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The firm had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.35 billion. During the same period in the previous year, the firm earned $0.30 earnings per share. The company's revenue was up 15.4% on a year-over-year basis. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Citigroup reiterated an "outperform" rating on shares of Option Care Health in a report on Thursday, July 31st. Barrington Research reiterated an "outperform" rating and issued a $38.00 price objective on shares of Option Care Health in a report on Thursday, July 10th. Finally, JMP Securities upped their price objective on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a report on Thursday, July 31st. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $35.75.

Insider Activity

In other news, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of Option Care Health stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $27.15 per share, with a total value of $977,400.00. Following the completion of the transaction, the director directly owned 375,390 shares of the company's stock, valued at approximately $10,191,838.50. This represents a 10.61% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Timothy P. Sullivan acquired 20,000 shares of Option Care Health stock in a transaction dated Thursday, August 21st. The shares were purchased at an average cost of $27.51 per share, with a total value of $550,200.00. Following the completion of the transaction, the director directly owned 49,229 shares of the company's stock, valued at $1,354,289.79. This trade represents a 68.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.64% of the stock is owned by corporate insiders.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.